Bipolar Disorder, Major Depressive Disorder (MDD), Schizophrenia
Conditions
Keywords
schizophrenia, cognitive impairments, brain imaging, bipolar disorder, major depressive disorder
Brief summary
Previous and our studies have shown that cognitive impairments are core symptoms of three major psychiatric disorders-schizophrenia, bipolar disorder, and major depressive disorder, and are associated with underlying brain dysfunction. However, the specific brain networks involved in cognitive impairments (cognitive impairment brain networks) in these disorders, as well as whether their neuroimaging features can be applied to cognitive assessment, diagnosis, and precision treatment, remain unclear. This study aims to identify cognitive impairment brain networks using publicly available large-scale datasets and clinical research, and to explore whether the neuroimaging features of these networks can be utilized for cognitive assessment, diagnosis, and treatment response prediction. First, a "sensitive cognitive assessment model for major psychiatric disorders" will be established through meta-analysis based on sensitive scales. Second, cognitive impairment brain networks will be identified using publicly available large-scale datasets combined with the lesion network mapping method, and their validity will be examined by assessing their non-randomness, reproducibility, symptom specificity, and disease specificity. Third, cognitive assessment and diagnostic models will be developed based on neuroimaging features of these networks. Finally, a combination of cross-sectional and longitudinal study designs will be used in a clinical trial to validate the identified networks and models, and a treatment response prediction model will be established based on the neuroimaging features of cognitive impairment brain networks. This study will advance the understanding of the neurophysiological mechanisms underlying cognitive impairment in major psychiatric disorders, promote the application of neuroimaging in psychiatric diagnosis and treatment, and improve traditional diagnostic, therapeutic, and cognitive assessment approaches.
Interventions
DEVICErepetitive transcranial magnetic stimulation (rTMS)
Patients will receive repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex (dlPFC).
Sponsors
Central South University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
We will recruit 100 patients each with schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD), who are either drug-naïve at first episode or have relapsed after discontinuing medication for more than one month, as well as 100 healthy controls. Before treatment, all participants will undergo demographic and clinical assessments, along with structural and resting-state functional magnetic resonance imaging (MRI) scans. After the baseline MRI scan, patients will receive repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex (dlPFC). Upon completion of the treatment course, clinical scale assessments and MRI scans will be repeated. Healthy controls will undergo clinical assessments and MRI scans at corresponding time points without receiving rTMS treatment.
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* 1, For Patients (SZ, BD, MDD): Diagnosis of schizophrenia (SZ), bipolar disorder (BD), or major depressive disorder (MDD) according to standard diagnostic criteria First-episode drug-naïve patients or patients who have relapsed after discontinuing medication for more than one month Aged 18-60 years Completion of at least 6 years of formal education 2, For Healthy Controls: Aged 18-60 years Completion of at least 6 years of formal education No current or past psychiatric disorders No first-degree relatives with psychiatric disorders No history of treatment with psychotropic medications or physical therapy for psychiatric disorders
Exclusion criteria
* Prior use of psychotropic medications or receipt of physical treatment for psychiatric disorders (for patient group) Contraindications to MRI scanning History of brain injury History of substance abuse Presence of other neurological disorders Presence of severe medical or systemic physical illnesses.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive changes | From enrollment to the end of treatment at 8 weeks | Cognitive Changes Assessed with the MATRICS Consensus Cognitive Battery (MCCB) after Repetitive Transcranial Magnetic Stimulation (rTMS) Intervention |
Countries
China
Contacts
CONTACTWenbin Guo, Ph.D.
STUDY_CHAIRWenbin Guo, Ph.D.
Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.
Outcome results
None listed